TNF and inflammatory bowel disease: The second dose of vaccine induced the most robust increase in the avidity of S-binding IgG in the healthy control group and patients with IBD treated with anti-IL-12/23, whereas patients with IBD treated with anti-TNF exhibited the greatest boost in the avidity of S-binding IgG after the third dose (Figure 7A).